Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 8630

Next Previous
Drug Profile

AZD 8630

Alternative Names: AMG-104; AZD-8630

Latest Information Update: 27 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca
  • Class Antiasthmatics; Immunoglobulin fragments
  • Mechanism of Action Thymic stromal lymphopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 04 Nov 2025 Amgen completes enrolment in phase-II clinical trials in Asthma (Treatment-experienced) in Ukraine, Turkey, Taiwan, Spain, South Korea, South Africa, Slovakia, Netherlands, Japan, Italy, Israel, Hong Kong, Germany, France, Denmark, Czech Republic, China, Chile, Belgium, Argentina and USA (Inhalation) (NCT06529419)
  • 19 Sep 2025 AstraZeneca completes a phase-I clinical trials in Asthma (In children, In adolescents) in USA (Inhalation) (NCT07065331)
  • 30 Aug 2025 Phase-II clinical trials in Asthma (Treatment-experienced) in Ukraine, Turkey, Taiwan, Spain, South Korea, South Africa, Slovakia, Netherlands, Japan, Italy, Israel, Hong Kong, Germany, France, Denmark, Czech Republic, China, Chile, Belgium, Argentina (Inhalation) (NCT06529419)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top